Radiotherapy Dose to Cardiac Substructures Linked to Arrhythmias
By Elana Gotkine HealthDay Reporter
TUESDAY, Aug. 27, 2024 -- For patients with locally advanced non-small cell lung cancer, radiotherapy dose to discrete cardiac substructures is associated with pathophysiologically distinct arrhythmia classes, according to a study published online in the August issue of JACC: CardioOncology.
Katelyn M. Atkins, M.D., Ph.D., from Cedars-Sinai Medical Center in Los Angeles, and colleagues conducted a retrospective analysis of 748 patients with locally advanced non-small cell lung cancer treated with radiotherapy to examine the association of distinct arrhythmia classes with cardiac substructure radiotherapy dose.
Of the participants, 128 (17.1 percent) experienced at least one grade ≥3 arrhythmia, with a median of 2.0 years to first arrhythmia. The researchers found that the two-year cumulative incidences were 8.0 percent for atrial fibrillation (AF), 2.7 percent for atrial flutter, 1.8 percent for non-AF and non-atrial flutter supraventricular tachyarrhythmia, 1.4 percent for bradyarrhythmia, and 1.1 percent for ventricular tachyarrhythmia or asystole. Pulmonary vein (PV) volume receiving 5 Gy was associated with AF after adjustment for baseline cardiovascular risk; left circumflex coronary artery volume receiving 35 Gy was associated with atrial flutter; PV volume receiving 55 Gy was associated with supraventricular tachyarrhythmia; right coronary artery volume receiving 25 Gy was associated with bradyarrhythmia; and left main coronary artery volume receiving 5 Gy was associated with ventricular tachyarrhythmia or asystole.
"These observations support continued fine mapping of cardiac substructure dose limits by considering cardiac physiological and pathophysiological mechanisms of disease," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
Stereotactic Body Radiotherapy Feasible After Radical Prostatectomy
TUESDAY, May 20, 2025 -- Post-radical prostatectomy (post-RP) stereotactic body radiotherapy (SBRT) is well tolerated, with patient-reported outcomes (PROs) comparable to those...
Survivorship Interest, Knowledge Limited in Head and Neck Cancer Survivors
TUESDAY, May 13, 2025 -- About one-third of head and neck squamous cell cancer (HNSCC) survivors who have undergone radiation therapy (RT) are interested in, prioritize, and have...
Ultra-Hypofractionated Radiotherapy Noninferior for Prostate Cancer
THURSDAY, May 8, 2025 -- Ultra-hypofractionated (UHF) radiotherapy delivered over two weeks is noninferior to conventionally fractionated (CF) radiotherapy delivered over eight...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.